Health Care·Pharmaceuticals·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.35 | N/A | +2.94% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.35 | N/A | +2.94% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains cautiously optimistic about future performance. They emphasized the need for strategic cost management and product innovation.
Management highlighted the importance of maintaining cost controls.
They expressed confidence in their product pipeline despite market challenges.
Prestige Consumer HE's earnings report shows a small EPS beat, which indicates some positive momentum. However, the stock's slight decline of 0.6% suggests that investors may have been expecting more comprehensive guidance or stronger revenue figures. The lack of revenue data and guidance could lead to uncertainty in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
REXFORD INDL RLTY IN REIT
May 12, 2014